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Purpose
Macrophage Activation Syndrome (MAS, alternatively
known as secondary Hemophagocytic Lymphohistiocytosis
(HLH)) is a potentially life-threatening complication of
many rheumatologic, infectious, and malignant diseases. It
is characterized by the acute onset of disseminated intra-
vascular coagulopathy and multi-system organ dysfunction
in the setting of overwhelming inflammation. As a result
of the poor understanding of disease pathogenesis, no con-
sensus exists regarding how best to diagnose and treat this
condition. Preliminary evidence in genetic forms of this
disease (known collectively as primary HLH) suggests a
critical role for IFNg and CD8+ T-lymphocytes.
Methods
We treated Wild-type (WT) and transgenic mice with
the Toll-like Receptor 9 (TLR9) agonist CpG, IFNg-
neutralizing antibody, and/or IL-10 receptor blocking
antibody via intraperitoneal injection as discussed
below.
Results
WT mice treated with CpG develop symptoms suggestive
of MAS, including pancytopenia, splenomegaly, hypercy-
tokinemia, hyperferritinemia, hepatitis, and coagulopathy.
Like primary HLH, CpG-induced MAS is also IFNg-
dependent, as mice who are IFNg-deficient or in whom
we have neutralized IFNg show a greatly abrogated phe-
notype. Accordingly, IFNg-deficient mice treated with
CpG have minimal IL-10, suggesting an IFNg-dependent
IL-10 response. In contrast, Rag knockout mice treated
with CpG show an intact IFNg response but blunted IL-
10 production, resulting in enhanced hepatitis. These
data suggest the role of IL-10 in MAS is to regulate
IFNg-mediated inflammation. To test this hypothesis, we
treated mice with CpG and concomitantly blocked IL-10
signaling. These mice developed cachexia, more severe
hepatitis & coagulopathy, worsened cytopenias, enhanced
cytokinemia and numerous splenic hemophagocytic
macrophages (HPCs). We also see expansion of the
populations of IFNg-mRNA producing CD4+ & CD8+
T-cells in the liver when we neutralize IL-10 signaling
when compared with CpG alone.
Conclusion
Repeated TLR9 stimulation induces an MAS-like syn-
drome mediated by IFNg and negatively regulated by
IL-10. IL-10 also appears to exert its negative effects on
distinct lymphocytic targets with organ specificity. Future
studies will refine the cellular sources and targets of IL-10
and IFNg, describe the mechanisms by which IL-10 works
to modify TLR and/or IFNg signaling, and define the func-
tional significance of HPCs. These insights will not only
further our understanding of MAS, but all cytokine storm
syndromes.
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